Amanda White

Associate

Amanda White
  • JD, Harvard Law School, 2019; Vice President of Operations, Harvard Law Entrpreneurship Project
  • PhD (Biomedical Sciences), University of California, San Diego, 2013
  • BS (Biology), magna cum laude, The College of New Jersey, 2006

Qualifications

  • Massachusetts, 2019
  • U.S. Patent and Trademark Office, Patent Agent, 2015
  • Boston Bar Association

Amanda White

Associate

Amanda White is an associate in Ropes & Gray's corporate department. Amanda’s practice is focused primarily on representing clients in business and intellectual property transactions, including technology licensing and transfer, supply and distribution agreements, and other strategic commercial arrangements in the biotechnology, pharmaceutical, and technology industries.

Before joining the firm, Amanda was an associate in the life sciences group of another premier international law firm where she represented public and private companies in all stages of maturity in the life sciences industry, including formation, venture financings, strategic alliances, licensing transactions, mergers and acquisitions, initial public offerings, and other transactions.

Prior to law school, Amanda was a patent agent where her practice focused on drafting and prosecuting U.S. and international patent applications and performing due diligence assessments, freedom to operate analyses, and patentability analyses in the areas of biotechnology and pharmaceuticals. Amanda obtained a Ph.D. in biomedical sciences, where her graduate work focused on investigation of the roles of nutrient availability and exercise in the regulation of muscle metabolism, insulin sensitivity and signaling, and mitochondrial bioenergetics. Prior to attending graduate school, Amanda worked as a biologist at a major pharmaceutical company performing lead-optimization pharmacology for the treatment of metabolic disorders.

Publications

  • Co-author, “Recent Growth Factors Driving Life Sciences Transactions,” Law360 (March 28, 2023)
  • Love JM, Bober BG, Orozco E, White A, Bremner SN, Lovering RM, Schenk S, Shah SB. mTOR regulates peripheral nerve response to tensile strain. J Neurophysiol, May 1;117(5)2075-2084, 2017.
  • White A, Mullen J, Potter K. USPTO Issues New Subject Matter Eligibility Examples for Life Sciences. May 2016.
  • White A, LaBarge SA, McCurdy CE, Schenk S. Knockout of STAT3 in skeletal muscle does not prevent high-fat diet-induced insulin resistance. Mol Metab, May 13;4(8):569-75, 2015.
  • White A, Philp A, Fridolfsson HN, Schilling JM, Murphy AN, Hamilton DL, McCurdy CE, Patel HH, Schenk S. High-fat diet-induced impairment of skeletal muscle insulin sensitivity is not prevented by SIRT1 overexpression. Am J Phisiol Endocrinol Metab, Nov 1;307(9):E764-72, 2014.
  • McGlory C, White A, Treins C, Drust B, Close G, Maclaren D, Campbell IT, Philp A, Schenk S, Morton J, Hamilton DL. Application of the (γ-32P) ATP kinase assay to study anabolic signaling in human skeletal muscle. J Appl Physiol, Mar 1;116(5):504-13, 2014.
  • White A, McCurdy CE, Philp A, Hamilton DL, Johnson CJ, Schenk S. Skeletal muscle-specific overexpression of SIRT1 does not enhance whole-body energy expenditure or insulin sensitivity in young mice. Diabetologia, 56:1629-37, 2013.
  • White A and Schenk S. NAD+/NADH and skeletal muscle mitochondrial adaptations to exercise. Am J Phisiol Endocrinol Metab, 303:E308-21, 2012.
  • White A and Murphy AN. Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. J Neurochem, 115:845-853, 2010.
  • White A and Murphy AN. Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. J Neurochem, 115:845-853, 2010.
  • Guan XM, Chen H, Dobbelaar PH, Dong Y, Fong TM, Gagen K, Gorski J, He S, Howard AD, Jian T, Jiang M, Kan Y, Kelly T, Kosinski J, Lin LS, Liu J, Marsh DJ, Metzger JM, Miller R, Nargund RP, Palyha O, Shearman L, Shen Z, Stearns R, Stribling S, Wang SP, White A, Yu H, Reitman ML. Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab,
    11:101-112, 2010.
  • Firth AL, White A, Yuan X-J. “Potassium Channels and Apoptosis: Application to Pulmonary Vascular Disease.” In, Apoptosis: Modern Insights into Disease from Molecules to Man. Editor: Victor Preedy. Science Publishers, 2010.
  • Firth AL, White A, Yuan X-J. Fibrinogen decreases thrombin-induced PAR-1-independent Ca2+ release in PAEC. Am J Respir Crit Care Med, 179, 2009.
  • Firth AL, Yau J, White A, Chiles P, Marsh J, Morris A, Yuan X-J. Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells. Am J Physiol Lung Cell Mol Physiol, 296:L979-986, 2009.
  • Frassetto A, Zhang J, Lao JZ, White A, Metzger JM, Fong TM, Chen RZ. Reduced sensitivity to diet-induced obesity in mice carrying a mutant 5HT6 receptor.
    Brain Res, 1236:140-144, 2008.
  • JD, Harvard Law School, 2019; Vice President of Operations, Harvard Law Entrpreneurship Project
  • PhD (Biomedical Sciences), University of California, San Diego, 2013
  • BS (Biology), magna cum laude, The College of New Jersey, 2006

Qualifications

  • Massachusetts, 2019
  • U.S. Patent and Trademark Office, Patent Agent, 2015
Cookie Settings